Pathology & Oncology Research

, Volume 17, Issue 3, pp 551–559 | Cite as

Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors

  • Ildikó VereczkeyEmail author
  • Orsolya Serester
  • Judit Dobos
  • Mónika Gallai
  • Orsolya Szakács
  • Zoltán Szentirmay
  • Erika Tóth


The pathogenesis of ovarian carcinomas is heterogeneous, with even the same entities showing great variance. In our study we investigated the mutations of the BRAF, KRAS, and p53 genes in serous and mucinous borderline tumors and in low grade and high grade serous and mucinous tumors. The mutations of BRAF and KRAS genes have been shown in 60% of borderline and low grade (well differentiated) serous and mucinous tumors, but very rarely in high grade (moderately and poorly differentiated) carcinomas. However mutations of p53 are very common in high grade tumors and this indicates a "dualistic" model of ovarian tumorigenesis. A total of 80 serous tumors, including serous borderline, low grade and high grade tumors, and 23 mucinous tumors, including borderline and invasive tumors were analysed for BRAF and KRAS mutations using real time PCR method followed by melting point analysis. P53 mutation was investigated by immunohistochemistry. We assumed mutation of the p53 gene when 100% of tumor cells showed strong nuclear positivity. We observed differences in genetic alterations in the development of the low grade tumors and between low and high grade tumors too. In some bilateral or stage II-III cases we observed differences between the mutation status of the left and right ovarian tumors and between the primary tumor and its implants. In one case in a tumor with micropapillary pattern showing high grade nuclear atypia we could detect mutations in both KRAS and p53 genes. The majority of our mucinous ovarian tumor cases showed a KRAS mutation. We have not found mutations of the BRAF and p53 genes in these cases. We have found as have others, that there is a dualistic pathway of ovarian carcinogenesis. In the majority of cases, low grade epithelial tumors develop in a stepwise manner due to genetic alterations of the members of MAP-kinase pathway; however mutation of the p53 gene is the key event in the development of high grade tumors.


Borderline Molecular Mucinous Ovary Pathogenesis Serous 



We are indebted to Professor Charles E Connolly for reviewing and correcting the paper.

This study was supported by grants of the EEA and Norwegian Financial Mechanisms in Hungary, Development of joint Hungarian and Norwegian strategy for cancer treatment by molecular methods. (Prevention, early diagnosis and therapy) No. 107/2008/NA and the Project co-financed by the European Social Fund through the Sectoral Operational Programme Human Resources Development 2007–2013. Project title: Advanced Research through postdoctoral programmes in fundamental and clinical medical sciences. Contract Code: POSDRU/89/1.5/S/60782


  1. 1.
    FIGO. Intenational Federation of Gynecology and Obstetrics (1971) Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand 50:1–7Google Scholar
  2. 2.
    Serov SF, Scully RE, Sobin LH (1973) International histologic Classification of Tumours. No. 9. Histological Typing of Ovarian Tumours. World Health Organization, GenevaGoogle Scholar
  3. 3.
    Österbeerg L, Akeson M, Levan K et al (2006) Genetic alterations of serous borderline tumors of the ovary compared to stage I serous ovarian carcinomas. Cancer Genet Cytogenet 167:103–108CrossRefGoogle Scholar
  4. 4.
    Singer G, Oldt R, Cohen Y et al (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95:484–486PubMedCrossRefGoogle Scholar
  5. 5.
    Singer G, Stöhr R, Cope L et al (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low —and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis (A mutational analysis with immunohistochemical correlation). Am J Surg Pathol 29(2):218–224PubMedCrossRefGoogle Scholar
  6. 6.
    Hsu C-Y, Bristow R, Cha M et al (2004) Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res 10:6432–6436PubMedCrossRefGoogle Scholar
  7. 7.
    Staebler A, Diebold J (2007) Molekularpathologie der epithelialen Ovarialneoplasien (Von der Phänotyp-Genotyp-Korrelation zu neuen Ansatzpunkten in Diagnostik und Therapie). Pathologe 28:180–186PubMedCrossRefGoogle Scholar
  8. 8.
    Ho C-L, Kurman RJ, Dehari R et al (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64:6915–6918PubMedCrossRefGoogle Scholar
  9. 9.
    Shih I-M, Kurman RJ (2004) Ovarian tumorigenesis (Review). Am J Path 164(5):1511–1518PubMedCrossRefGoogle Scholar
  10. 10.
    Kurman RJ, Shih I-M (2008) Pathogenesis of ovarian cancer. Lessons from morphology and molecular biology and their implications. Int J Gynecol Pathol 27(2):151–160PubMedGoogle Scholar
  11. 11.
    Seidman JD, Horkayne-Szakaly I, Haiba M et al (2004) The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol 23:41–44PubMedCrossRefGoogle Scholar
  12. 12.
    Hart WR (2005) Borderline epithelial tumors of the ovary. Mod Path 18:33–50CrossRefGoogle Scholar
  13. 13.
    Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18:S19–S32PubMedCrossRefGoogle Scholar
  14. 14.
    Christie M, Oehler MK (2006) Molecular pathology of epithelial ovarian cancer. J Br Menopause Soc 12(2):57–63PubMedCrossRefGoogle Scholar
  15. 15.
    Singer G, Kurman RJ, Chang H-W et al (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160:1223–1228PubMedCrossRefGoogle Scholar
  16. 16.
    Shih I-M, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumors: new insight and old challenges. Clin Cancer Res 11:7273–7279PubMedCrossRefGoogle Scholar
  17. 17.
    Sridhar SS, Hedley D, Siu LL (2005) Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 4(4):677–685PubMedCrossRefGoogle Scholar
  18. 18.
    Pohl G, Ho C-L, Kurman RJ (2005) Inactivation of the Mitogen-Activared Protein Kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65(5):1994–2000PubMedCrossRefGoogle Scholar
  19. 19.
    Sieben NLG, Macropoulos P, Roemen GMJM et al (2004) In ovarian neoplasms BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol 202:336–340PubMedCrossRefGoogle Scholar
  20. 20.
    Mayr D, Hirschmann A, Löhrs U et al (2006) KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103:883–887PubMedCrossRefGoogle Scholar
  21. 21.
    Ueda M, Toji E, Noda S (2007) Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. Int J Gynecol CancerGoogle Scholar
  22. 22.
    Wang L, Arnold K (2003) Common mutations prevalent in low-grade ovarian cancers. J Nat Cancer Inst 95(6):417–418CrossRefGoogle Scholar
  23. 23.
    Garrett AP, Lee KP, Colitti CR et al (2001) K-RAS mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 20:244–251PubMedCrossRefGoogle Scholar
  24. 24.
    Vang R, Shih I-M, Salani R et al (2008) Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol 32(11):1667–1674PubMedCrossRefGoogle Scholar
  25. 25.
    Köbel M, Hunstman D, Gilks CB (2008) Critical molecular abnormalities in high grade serous carcinoma of the ovary. Expert Rev Mol Med 10:e22PubMedCrossRefGoogle Scholar
  26. 26.
    Russell SEH, McCluggage WG (2004) A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. L Pathol 203:617–619CrossRefGoogle Scholar
  27. 27.
    Lee Y, Miron A, Drapkin R et al (2007) A candidate precursor to serous sarcinoma that originates in the distal fallopian tube. J Pathol 211(1):26–35PubMedCrossRefGoogle Scholar
  28. 28.
    Goodman MT, Shvetsov YB (2009) Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004. Cancer Epidemiol Biomarkers Prev 18(1):132–139PubMedCrossRefGoogle Scholar
  29. 29.
    Tong G-X, Chiriboga L, Hamele-Bena D et al (2007) Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin? Mod Pathol 20:856–863PubMedCrossRefGoogle Scholar
  30. 30.
    Roh MH, Kindelberger D, Crum CP (2009) Serous tubal intraepithelial carcinoma and dominant ovarian mass: clues to serous tumor origin? Am J Surg Pathol 33(3):376–383PubMedCrossRefGoogle Scholar
  31. 31.
    Leiato MM, Soslow RA, Baergen RN et al (2004) Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol 93:301–306CrossRefGoogle Scholar
  32. 32.
    Morice P, Uzan C, Kane A et al (2009) Prognostic factors of patients with advanced stage serous borderline tumors of the ovary. J Clin Oncol 27:15s (suppl;abstr 5573)CrossRefGoogle Scholar
  33. 33.
    Sieben NL, Roemen GMJM, Oosting J (2006) Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J Pathol 210:405–411PubMedCrossRefGoogle Scholar
  34. 34.
    Krishnamurti U, Sasatomi E, Swalsky PA (2005) Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int J Gynecol Pathol 24:56–61PubMedGoogle Scholar
  35. 35.
    Diebold J, Seemuller F, Lohrs U (2003) K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy. Lab Invest 83:251–258PubMedGoogle Scholar
  36. 36.
    Zanotti KM, Hart WR, Kennedy AW (1999) Allelic imbalance on chromosome 17p13 in borderline (low malignant potential) epithelial ovarian tumors. Int J Gynecol Pathol 18:247–253PubMedCrossRefGoogle Scholar
  37. 37.
    Gu J, Roth LM, Younger C et al (2001) Molecular evidence for the independent origin of extraovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 93:1147–1152PubMedCrossRefGoogle Scholar
  38. 38.
    Lu KH, Bell DA, Welch WR et al (1998) Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 58:2328–2330PubMedGoogle Scholar
  39. 39.
    Davies H, Bignell GR, Cox C et al (2002) Mutations of BRAF gene in human cancer. Nature 417:949–954PubMedCrossRefGoogle Scholar
  40. 40.
    Cheng EJ, Kurman RJ, Wang M et al (2004) Molecular genetic analysis of ovarian serous cystadenomas. Lab Invest 84:778–784PubMedCrossRefGoogle Scholar
  41. 41.
    Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary: a distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20:1319–1330PubMedCrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2010

Authors and Affiliations

  • Ildikó Vereczkey
    • 1
    Email author
  • Orsolya Serester
    • 1
  • Judit Dobos
    • 1
  • Mónika Gallai
    • 1
  • Orsolya Szakács
    • 1
  • Zoltán Szentirmay
    • 1
  • Erika Tóth
    • 1
  1. 1.Department of Surgical and Molecular PathologyNational Institute of OncologyBudapestHungary

Personalised recommendations